Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has earned a consensus rating of “Buy” from the eleven research firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $16.25.

A number of brokerages have recently commented on KPTI. BidaskClub downgraded shares of Karyopharm Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 31st. ValuEngine downgraded shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 31st. Royal Bank Of Canada assumed coverage on shares of Karyopharm Therapeutics in a research note on Thursday. They set an “outperform” rating and a $14.00 target price for the company. Zacks Investment Research upgraded shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research note on Thursday, July 6th. Finally, Cantor Fitzgerald set a $18.00 target price on shares of Karyopharm Therapeutics and gave the stock a “buy” rating in a research note on Saturday, June 24th.

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) traded up 4.07% during midday trading on Friday, reaching $11.00. The company’s stock had a trading volume of 432,710 shares. The stock’s 50 day moving average is $9.28 and its 200 day moving average is $9.87. The stock’s market capitalization is $518.52 million. Karyopharm Therapeutics has a 12 month low of $6.27 and a 12 month high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.64) EPS for the quarter, meeting analysts’ consensus estimates of ($0.64). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 70.42%. During the same period in the prior year, the firm posted ($0.84) earnings per share. The company’s revenue was down 95.0% on a year-over-year basis. On average, analysts forecast that Karyopharm Therapeutics will post ($2.68) EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of KPTI. Vanguard Group Inc. lifted its stake in shares of Karyopharm Therapeutics by 31.1% during the 2nd quarter. Vanguard Group Inc. now owns 1,621,420 shares of the company’s stock worth $14,675,000 after buying an additional 384,658 shares during the last quarter. Teachers Advisors LLC raised its stake in Karyopharm Therapeutics by 915.0% in the 1st quarter. Teachers Advisors LLC now owns 420,563 shares of the company’s stock worth $5,400,000 after purchasing an additional 379,127 shares in the last quarter. Iguana Healthcare Management LLC acquired a new stake in Karyopharm Therapeutics in the 1st quarter worth about $3,531,000. EAM Investors LLC acquired a new stake in Karyopharm Therapeutics in the 1st quarter worth about $3,462,000. Finally, Candriam Luxembourg S.C.A. raised its stake in Karyopharm Therapeutics by 154.7% in the 2nd quarter. Candriam Luxembourg S.C.A. now owns 438,000 shares of the company’s stock worth $3,964,000 after purchasing an additional 266,000 shares in the last quarter. Institutional investors own 58.97% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Karyopharm Therapeutics Inc. (KPTI) Receives Consensus Rating of “Buy” from Brokerages” was reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/09/17/karyopharm-therapeutics-inc-kpti-receives-consensus-rating-of-buy-from-brokerages.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.